SEC Form 4 · accession 0001415889-17-002002
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank L Jaksch Jr.
Officer — CEO · Director
Period of report
Dec 21, 2017
Accepted (ET)
Dec 26, 2017 · 4:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 21, 2017 | M | 58,400 | $4.50 | A | 259,957 | D | |
| Common StockF1 | Dec 21, 2017 | S | 58,400 | $6.19 | D | 201,557 | D | |
| Common Stock | holding | — | — | — | 2,075,052 | I | By Black Sheep, FLP |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (right to buy) | $4.50 | Dec 21, 2017 | M | 58,400 | D | Apr 21, 2009 | Apr 21, 2018 | Common Stock | 58,400 | 224,934 | D |
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted on November 17, 2017. The options exercised and sold were scheduled to expire on April 21, 2018 and Mr. Jaksch sold the shares so that the proceeds can be used to cover the exercise payment and applicable withholding taxes due.